Table 1. Remotely Collected Self-Reported Information Compared to Investigator-Reported Information.
N | Agreement | kappa | |
---|---|---|---|
Diagnosis: PD/nonPD1 | 418 | 95.0% | 0.562 |
Medication: On PD medication or not2 |
273 | 96.0% | 0.77 |
Medication: Type of PD medication | 244 | 91.9% | 0.893 |
Ldopa preparations | 864 | 97.6% | |
DA agonists | 654 | 90.5% | |
Ldopa preparations plus DA agonists | 744 | 91.0% | |
Other PD medications3 | 194 | 86.5% | |
Dyskinesias: Present/absent | 87.5% | 0.502 |
Mean interval between reports is 6.55 months
Interval between reports is ≤ 2 months
Other PD medications include monoamine oxidase B inhibitors, catechol-o-methyl transferase inhibitors, amantadine, anticholinergics.
Investigator's report of medication at baseline is gold standard.